S267: PHARMACOKINETICS/PHARMACODYNAMICS, SAFETY AND EFFICACY OF CRIZANLIZUMAB IN PATIENTS WITH SICKLE CELL DISEASE AGED 12 TO <18 YEARS: 2-YEAR DATA FROM THE PHASE 2 SOLACE-KIDS STUDY
Matthew Heeney1,
David Rees,
Mariane de Montalembert,
Isaac Odame,
Yasser Wali,
Sarfaraz Sayyed,
Velusamy Shanmuganathan Muthusamy,
Anisha E. Mendonza,
Michele Nassin,
Deborah Keefe,
Julie Kanter
Affiliations
Matthew Heeney1
1 Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, Boston, United States
David Rees
2 King’s College Hospital, Department of Paediatric Haematology, London, United Kingdom
Mariane de Montalembert
3 Hôpital Universitaire Necker-Enfants Malades, Paris, France
Isaac Odame
4 The Hospital for Sick Children (SickKids) and the University of Toronto, Toronto, Canada
Yasser Wali
5 Sultan Qaboos University, Child Health Department, Muscat, Oman
Sarfaraz Sayyed
6 Novartis Healthcare Pvt. Ltd., Hyderabad, India
Velusamy Shanmuganathan Muthusamy
6 Novartis Healthcare Pvt. Ltd., Hyderabad, India
Anisha E. Mendonza
7 Novartis Institutes for BioMedical Research, Cambridge, United States
Michele Nassin
8 Novartis Pharmaceuticals Corporation,, East Hanover, United States
Deborah Keefe
8 Novartis Pharmaceuticals Corporation,, East Hanover, United States
Julie Kanter
9 University of Alabama-Birmingham, Division of Hematology-Oncology, Birmingham, United States
